ArticleJournal of fluorescence2025
Targeted Fluorescent Polysaccharide Platform for Solute Carrier Protein PCNA Detection and Cervical Squamous Cell Carcinoma Inhibition.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical squamous cell carcinoma (CSCC) remains one of the leading causes of cancer-related deaths among women. In advanced stages, treatment is often hindered by drug resistance and severe toxic side effects. The solute carrier protein PCNA, a key regulatory factor in the cystine/glutamate antiporter system, promotes tumor progression by maintaining cellular redox balance and inhibiting ferroptosis, making it a highly promising therapeutic target. In this study, a fluorescence detection platform based on a chitosan (CS)-modified cobalt(II) coordination polymer (CP1) was developed for the highly sensitive detection of PCNA activity. By loading cyclic peptide compound 1, the platform also achieves dual diagnostic and therapeutic functions (CS@CP1@1). Upon interaction with PCNA, the fluorescence intensity of the probe is significantly reduced due to the specific binding between CP1 and PCNA enabling precise fluorescence signal response. The developed sensing platform exhibits a broad linear detection range (0.5-60 U/L) and an ultra-low limit of detection (LOD = 0.14 U/L). Cell experiments further confirmed that this system effectively inhibits PCNA activity and significantly reduces the proliferation of CSCC cells, demonstrating promising therapeutic potential.
Indexed as
Identifiers
40512372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.